Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) issued its earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08), Zacks reports.
Vigil Neuroscience Stock Down 4.3 %
Shares of VIGL opened at $2.02 on Friday. The business’s 50 day moving average is $2.34 and its two-hundred day moving average is $2.79. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06. The firm has a market cap of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on VIGL. William Blair began coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating for the company. JMP Securities reiterated a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. HC Wainwright decreased their price target on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, Wedbush decreased their price target on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a report on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vigil Neuroscience presently has an average rating of “Buy” and an average price target of $16.25.
Vigil Neuroscience Company Profile
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Further Reading
- Five stocks we like better than Vigil Neuroscience
- How to Invest in Blue Chip Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Hang Seng index?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Where Do I Find 52-Week Highs and Lows?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
